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Abstract
Walters, Nicole. M.S. Department of Biochemistry and Molecular Biology, Wright
State University, 2021. The F-box protein FBW7 negatively regulates the stability of
ERK3 protein.

Extracellular signal-regulated kinase 3 (ERK3) is a member of the atypical
mitogen-activated protein kinase (MAPK) subfamily, whose members have been shown to
play important roles in a number of cellular processes including proliferation,
differentiation, migration, and apoptosis. While signals regulating ERK3 kinase activity
remain unclear, ERK3 is known to be an unstable protein with function tightly regulated
via ubiquitination and proteasomal turnover. The deubiquitinating enzyme USP20 has
been shown to regulate ERK3 by stabilizing the kinase, but presently, no destabilizing
ubiquitin ligases have been identified. The SKP1-CUL1-F-box protein (SCF) E3 ligases
are a subfamily of ubiquitin E3 ligases composed of the adaptor protein SKP1, the scaffold
protein Cullin1 (CUL1) and a specific F-box protein. As a component of the SCF-E3 ligase
complex, the F-box protein recruits specific substrates to the E3 complex via its substrate
interaction domain. Many substrates of SCF-E3 ligases contain a so-called phosphodegron, a phosphorylated S/TXXXS/T consensus motif recognized by F-box proteins such
as FBW7 and β-TRCP. Remarkably, the ERK3 protein sequence contains a number of
these potential phosphorylated S/TXXXS/T motifs. As such, an siRNA screening was
performed to identify potential F-box protein(s) capable of regulating ERK3 protein level.
Knockdown of FBW7 resulted in a remarkable increase in ERK3 protein level, suggesting
iii

FBW7 negatively regulates ERK3 protein. This was confirmed upon overexpression of
FBW7, which led to a significant decrease in ERK3 protein level. Furthermore, we have
demonstrated FBW7 downregulates ERK3 protein stability in a manner dependent on its
F-box domain. To determine which domain of ERK3 is central to regulation by FBW7,
several ERK3 deletion mutants were generated. Using these mutants, we found the ERK3
C34 domain is required for FBW7 regulation of ERK3 and is itself sufficient for FBW7ERK3 interaction. Taken together, these results demonstrate that FBW7 negatively
regulates ERK3 protein stability in a manner dependent on the FBW7 F-box and ERK3
C34 domains.
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I.

Introduction

A.

Mitogen Activated Protein Kinases (MAPKs)
One of the well-conserved pathways throughout evolution is that of the MAPK family,

a group of serine/threonine kinases which work in the cell to convert extracellular stimuli
into a transmissible intercellular signal, resulting in a cascade of responses (Widmann C
et. al, 1999). MAPK family members cover a diverse array of functions, having roles
ranging from gene expression to cellular differentiation and cell survival to apoptosis
(Cargnello and Roux, 2011). Provided their extensive roles, it is unsurprising that MAPK
family members have been implicated in a variety of diseases including Alzheimer’s
disease, Parkinson’s disease, and numerous cancers (Kim and Choi, 2010).
The basic pathway for MAPK signal transmission begins when an external stimulus
activates a MAPKK kinase (MAPKKK) such as Raf, usually through phosphorylation or
stimulation by a member of the Ras/Rho family. This MAPKKK in turn activates a MAPK
kinase (MAPKK) via phosphorylation. Upon its activation, a MAPKK typically
phosphorylates a MAPK, subsequently stimulating MAPK activity (Fig. 1) (Robbins D et.
al, 1993). However, it should be noted that not all MAPKs are activated by a MAPKK.
Rather, the ability to be phosphorylated by a MAPKK provides a basis for subdivision of
MAPKs into two categories: conventional and atypical (Kostenko et al, 2011).
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Figure 1. Schematic representation of various MAPK family pathways (Cargnello and
Roux, 2011)
Conventional MAPKs such as ERK1/2 are activated by MAPKKs (e.g. MEK1/2)
through dual phosphorylation of the activation loop, a conserved TXY motif located within
the MAPK kinase domain (Fig. 2). Conversely, atypical MAPKs are much more
ambiguous in their activation, requiring pathways not defined by the classical three-tiered
kinase cascades. Atypical MAPKs further differ from their conventional counterparts in
their alternative structure. Most noteworthy is the difference in activation loop, with
atypical MAPKs lacking the traditional TXY motif. In the case of ERK3/4, the activation
loop TXY is replaced by an SEG motif, a region lacking the phospho-acceptor tyrosine
residue required for MAPKK-mediated regulation. Additionally unique to ERK3/4 is the
2

presence of a conserved C34 domain not found in conventional MAPKs (Fig. 2) (Kassouf
and Sumara, 2020). ERK3 itself further contains an entirely unique extended C-terminus,
discussed further in the following section.

Figure 2. Schematic representation of human MAPK structures (Cargnello and Roux,
2011). C34: conserved in ERK3 and ERK4. NLS: nuclear localization signal. TAD:
transactivation domain.
B.

Extracellular Signal Regulated Kinase 3 (ERK3)
Amongst these more elusive atypical MAPKs is ERK3, a kinase initially cloned in rats

by nature of its homology to the conventional MAPK ERK1, with which the ERK3 kinase
domain shares 50% homology (Boulton et al, 1991). However, apart from this, ERK3
shares very little with its conventional counterpart, and much about the kinase remains to
be elucidated. Regarding its function, ERK3 has primarily been linked to the cell cycle,
with increased ERK3 mRNA connected to cell cycle exit and terminal differentiation in
3

p19 carcinoma cells (Tanguay et al, 2010). Furthermore, ERK3 has been shown to inhibit
S-phase progression in fibroblasts (Coulombe et al, 2003), potentially through its
interaction with cell-cycle regulators (Sun et al, 1994). The upregulation of ERK3 mRNA
has additionally been correlated with an increased differentiation state of both neuronal and
muscular cells (Coulombe et al, 2003).
This cell cycle linkage to ERK3 is further seen in the localization of ERK3 itself. In
humans, ERK3 is found both in the nucleus and the cytoplasm. Interestingly, this
localization was shown by Bind et al (2004) to be dependent on carboxy-terminal cleavage
of the ERK3 protein, which resulted in its translocation from the Golgi apparatus to the
nucleus. The study further showed that cleavage sites retained the catalytic domain (1-376)
[sic] and as many as 224 amino acids of the carboxy-terminus. As cells moved into the M
phase, translocation of truncated ERK3 to the nucleus increased, with ERK3 returning to
the Golgi upon the next cycle (Bind et al, 2004). Whereas most MAPKs are stable proteins,
ERK3 protein is unstable with a short half-life (English, 1999). Interestingly, though most
unstable protein kinases show destabilization linked to their enzymatic activation, ERK3
is instead reliably phosphorylated in the C-terminal (Ser684, Ser688, Thr698, Ser705) (Tanguay
et al, 2010), and subsequently stabilized, in a manner dependent on the cell cycle (Pokrass
et al, 2020).
This phosphorylation-dependent cell cycle regulation of ERK3 likely occurs, in part,
through the ERK3 C-terminus, whose phosphorylation has been linked to ERK3
stabilization (Hershko et al, 1998). Interestingly, the kinetics of ERK3 dephosphorylation
are parallel to the degradation of cyclin B1, occurring in late mitosis and early G1. ERK3
is shown to be hyperphosphorylated and accumulate during mitosis before
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dephosphorylation and degradation during the progression of cells into the G1 phase,
potentially as a result of C-terminal phosphorylation by cyclin B-Cdk1 (Tanguay et al,
2010). This is of particular significance as, unlike most MAPKs, ERK3 is regulated
primarily through its rate of turnover (Coulombe et al, 2003).
In fact, ERK3 is highly unstable and continuously degraded via the ubiquitinproteasome system, and is believed to be controlled through alteration of its ubiquitination
status. This targeting of ERK3 to the 26S proteasome was initially shown by Coulombe et
al (2004) to be independent of ERK3 catalytic activity or C-terminal extension, and to
require ubiquitination of the N-terminal kinase domain. The precise underlying
mechanisms and importance of each region of ERK3 in the regulation of its protein stability
remains to be elucidated.
Structurally, ERK3 protein encompasses three basic domains: a kinase domain at the
N-terminus, a C34 domain shared with ERK4, and a C-terminal extension (Fig. 2) (Zhu et
al, 1994). As mentioned above, the ERK3 kinase domain contains an SEG activation loop
which remains phosphorylated in vivo (Cheng et al, 1996). This activation loop
phosphorylation is important for ERK3 kinase activity and ERK3 promotion of lung cancer
migration and invasiveness (Elkhadragy et al, 2018). Additionally, phosphorylation of the
activation loop Ser189 stimulates the intrinsic catalytic activity of ERK3 and allows it to
complex with substrates such as MK5 (Deleris et al, 2008).
Located in the middle of ERK3 protein is the C34 domain, a region conserved
throughout evolution and shared only with ERK4. This domain may have a role in proteinprotein interaction, but its precise function remains unknown. (Coulombe and Meloche,
2007). Entirely unique to ERK3 is its extended C-terminus, a serine and threonine rich
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region (Meloche et al, 1996) whose conservation throughout evolution suggests
importance. One study has indicated the C-terminal is involved in mediating protein
interactions (Sun et al, 2006) in addition to its importance in the ERK3 kinase activity
responsible for promoting cellular migration and invasion in lung cancer (Elkhadragy et al,
2020). As mentioned above, the C-terminus is additionally implicated in regulation of
ERK3 stability, becoming hyperphosphorylated during entry into mitosis and leading to
stabilization of ERK3 (Tanguay et al, 2010).
C.

ERK3 in cancer
ERK3 dysregulation is highly implicated in various forms of cancer including breast,

non-small cell lung (NSCLC), gastric, and colon cancers (Lei et al, 2014). In head and neck
cancers, ERK3 was found to be upregulated by BMI1, resulting in increased cancer cell
migration and invasion (Elkhadragy et al, 2017). In gastric cancer, ERK3 protein levels
were shown to be elevated in both the primary site and metastatic lymph nodes (Liang et
al, 2005). K-Ras, a Ras isoform frequently mutated in a number of cancers (Prior et al,
2012), was recently shown to require ERK3 for its promotion of NSCLC tumor growth
(Bogucka et al, 2021). In breast cancer, MDA-MB-231 cells were shown to respond to
elevated ERK3 levels with morphological change facilitating invasion and, subsequently,
an increased rate of migration (Al-Mahdi et al, 2015). Upon overexpression of the ERK3stabilizing enzyme USP20, HeLa cells were found to reorganize and migrate in an ERK3dependent manner (Mathien et al, 2017). Increased pulmonary invasiveness has also been
attributed to the ERK3 mutation 290P/V, which was found to increase ERK3 localization
into the cytoplasm (Alsaran et al, 2017). Similarly, ERK3 was shown to promote
invasiveness through phosphorylation and successive activation of the oncoprotein SRC3
6

(Long et al, 2012). ERK3 may also play a role in treatment-resistant lung carcinoma
through promoting TDP2 activity, thereby overcoming therapeutic topoisomerase-2
inhibitors (Bian et al, 2016). Conversely, ERK3 has been shown to function as a tumor
suppressor in melanoma formation and metastasis (Chen et al, 2019) in response to BRAF
signaling (Chen, 2017). ERK3 upregulation was also implicated in the reduction of
intrahepatic cholangiocarcinoma cell growth following combination treatment with cancer
therapeutics metformin and arsenic trioxide (Ling et al, 2017). Finally, upregulation of
ERK3 was shown to suppress migration of non-melanoma skin cancer cells in response to
ΔNp63α signaling (Alshammari et al, 2021).
D.

Post-translational modification of ERK3
ERK3 activity is primarily mediated through its posttranslational modifications. As

mentioned, primary regulation of ERK3 occurs through its continuing degradation by the
ubiquitin-proteasome pathway, and ERK3 is targeted for degradation through its
polyubiquitination, although a single ubiquitin chain has been found to be sufficient
(Coulombe et al, 2004).
Continuing ubiquitination of ERK3 occurs independent of ERK3 activation loop
phosphorylation, kinase activity, and the C-terminal extension. This ubiquitination does,
however, require the N-terminus (Coulombe et al, 2004), which is ubiquitinated
independent of lysine and requires a ubiquitin-conjugating enzyme (E2) to fuse the free
ERK3 NH2 terminus with the C-terminal glycine of the ubiquitin molecule. Two regions
of the N-terminus confer instability to ERK3 and were accordingly named N-terminal
degradation region 1 and -2 (NDR1 and NDR2). NDR1 occupies the first 15 amino acids
of the ERK3 kinase domain and NDR2 is located between amino acids 38 and 73
7

(Coulombe et al, 2003). These regions were shown to be both necessary and sufficient to
target ERK3 to the 26S proteasome (Coulombe et al, 2003), and N-terminal Met73 was later
identified as a ubiquitination site (Coulombe et al, 2004). Expectedly, addition of a large
N-terminal sequence tag stabilizes ERK3 by preventing its ubiquitination via N-terminal
methionine (NDR2), indicating the importance of the N-terminal in ERK3 stability
(Coulombe et al, 2004).
USP20 has arisen as an important regulator of ERK3 stability through its function as a
deubiquitinating enzyme. USP20 directly binds and deubiquitinates ERK3, resulting in
ERK3 stabilization (Mathien et al, 2017). It is through this deubiquitylation of ERK3 that
USP20 contributes to regulation of cell adhesion and migration (Chen et al, 2019).
Phosphorylation is a major form of posttranslational modification used to regulate
protein activity in cells. Though ERK3 activation is not regulated like conventional
MAPKs, ERK3 phosphorylation does stabilize the protein in a cell cycle-dependent
manner. The C-terminal extension of ERK3 contains four novel phosphorylation sites
(Ser684, Ser688, Thr698, Ser705), each followed by a proline residue, allowing the residues to
become Cdk substrates. Each of these sites, including their surrounding amino acids, are
highly conserved in mammals. Upon entrance into mitosis, these sites are phosphorylated
and stabilize ERK3, leading to accumulation of ERK3 (Tanguay et al, 2010). Cyclin BCdk1, a major Thr698 kinase has been linked to the cyclical nature of ERK3
phosphorylation, with cyclin B-Cdk1 activity peaking during mitosis and being required
for normal entry into mitosis in addition to catalyzing ERK3 phosphorylation in vitro
(Aredia et al, 2015). Similarly, cyclical dephosphorylation of ERK3 occurs at the exit of
mitosis and entrance into G1, mediated by the proline-directed phosphatases Cdc14A and

8

Cdc14B, which work in opposition to the action of Cdks to regulate various cell cycle
events (Kostenko et al, 2011). Phosphorylation sites Ser189 and Ser386 in ERK3’s unique
activation loop motif have been identified, though these sites are not responsible for
hyperphosphorylation of ERK3 during mitosis (Deleris et al, 2008). Ser386 has been found
to lie within a putative MK5 consensus sequence, and phosphorylation of the site is
required for the formation of a stable complex with the substrate MK5 (Tanguay et al,
2010). Constitutively phosphorylated in vivo, Ser189 has also been identified as necessary
for MK5 activation, ATP binding, and ERK3’s effect on migration and invasiveness
(Elkhadragy et al, 2018).
ERK3 stability is further regulated through its hydroxylation by PHD3, which protects
ERK3 from degradation by preventing its ubiquitination. Hydroxylase inhibition has been
found to significantly impact the ERK3 interaction of 15 proteins, four of which are linked
to ubiquitination (HUWE1, UBE2Am), ubiquitin recognition (RAD23b), and the
proteasome (ECM29). Unsurprisingly, reduced hydroxylation was also found to increase
proteasomal degradation of ERK3 directed by HUWE1 and UBE3A. Hydroxyl-mediated
inhibition of degradation occurs through the hydroxylation of Pro25, which is located
between the N-terminal destabilization regions NDR1/2. In a mimic of the N-terminal tag
experiment mentioned, it is possible hydroxylation of this amino acid serves to block the
methionine ubiquitination site of the N-terminus, thereby preventing direction to the 26S
proteasome (Rodriguez et al, 2016).
E.

Ubiquitination and SCF complex
Ubiquitin-mediated degradation is a fundamental biological system in which proteins

are targeted for degradation by the 26S proteasome through covalent ligation of the target
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protein to ubiquitin molecules. Polyubiquitination provides a recognition signal for the 19S
regulatory subunit of the 26S proteasome (Hershko et al, 1988). Attachment of ubiquitin
molecules requires the sequential action of three enzymes (E1, E2, E3). E1 begins by
activating the C-terminal glycine of ubiquitin using ATP. Using a ubiquitin adenylate
intermediate, E1 then binds ubiquitin before transferring the active molecule to the active
site cysteine residue of the ubiquitin-carrier protein E2. E2 either fully transfers ubiquitin
to E3 or participates in the ubiquitination of the substrate. Finally, ubiquitin-protein ligase
E3 links ubiquitin with the substrate protein, usually via lysine residue (Fig. 3) (Wang et
al, 2012). The E3 ligase is responsible for conferring specificity through its discrimination
of the substrate (Deshaies and Joazeiro, 2009).

Figure 3. Schematic representation of ubiquitination by SCF E3 ligase (Wang et al,
2012).
However, it should be noted that not all substrates of E3 molecules require lysine for
ubiquitination. In the case of ERK3, ubiquitin conjugation to the N-terminal methionine
mediates degradation independent of lysine, though the detailed mechanism is not yet
known (Coulombe et al, 2004). Regardless, the inherent adaptability of E3 ligases allows
for ubiquitination of these lysine-independent molecules.
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Several E3 ligases are modular, having core scaffolding with interchangeable substratetargeting subunits, thereby allowing one piece of core machinery to ubiquitylate many
different substrates. Amongst these is the cullin-ring ligase family (CRL) of complexes,
which serve as archetypes for modular ubiquitin ligases. Best characterized within this
family are the SCF ligases, named for their components: s phase kinase-associated protein
1 (SKP1), cullin 1 (CUL1), and an F-box protein (Skaar et al, 2013). Assembly of the SCF
ligase begins with the scaffold protein CUL1 recruiting the small RING protein RBX1,
which directs the E2 enzyme to the E3 ligase. CUL1 next binds SKP1 and a variable F-box
protein, which dictates substrate specificity. SKP1 links the F-box protein to CUL1 by
binding to an F-box protein’s F-box domain (Zhou et al, 2013).
An F-box protein is responsible for recruiting target proteins to the SCF E3 ligase
complex. Canonically, F-box proteins bind to short, defined degradation motifs otherwise
known as degrons, a process mediated by tight regulation of both the F-box’s proteinsubstrate interface and the F-box proteins themselves (Zhang et al, 2020). The best
characterized of these are phosphorylation-dependent, requiring phosphorylation of the
degron within the substrate. Phospho-degrons provide a method of fine-tuning substrate
recognition by setting a threshold of kinase activity that creates a direct linkage to a
regulatory pathway. Additional priming phosphorylation can provide an increased
complexity and stringency to substrate recognition (Guharoy et al, 2016).

F.

F-box Protein Family
Despite the interaction with SCF allowing few invariant positions, F-box proteins make

up a large, diverse family, with 69 different proteins having been identified in humans.
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Initially observed as a region of homology among various proteins in Neurospora crassa
(Kumar and Paietta, 1995), the F-box is a widespread motif required for a number of
protein-protein interactions (Bai et al, 1996). F-box proteins are unique to eukaryotes and
are composed of the F-box motif at the amino terminal and another motif at the carboxy
terminal, usually either a series of leucine rich or WD40 repeats (Kipreos and Pagano,
2000). Nonetheless, F-box proteins may have a wide range of secondary motifs which
target a variety of substrates, allowing the core SCF to select hundreds of different proteins
for degradation (Jin et al, 2004). As proposed by the Human Genome Organization
(Kipreos and Pagano, 2000), following a pattern introduced by Cenciarelli et al (1999),
nomenclature for members of the F-box family is based on their substrate interaction
domains and classifies the proteins as three major groups: FBXLs, which contain leucinerich repeats (LRRs); FBXWs, which have WD40 repeats; and FBXOs, which contain other
binding motifs.
G.

FBW7
FBW7 is a well-documented member of the FBXW family which regulates phospho-

dependent protein degradation. FBW7 is best known for its role in the ubiquitination and
degradation of oncoproteins. FBW7 negatively regulates cancer cell division and growth
by degrading crucial proto-oncogenes such as myc, cyclin E, NOTCH, and Jun, each of
which can drive proliferation and tumorigenesis (Welcker et al, 2004; Strohmaier et al,
2001; Klinakis et al, 2006; Wei et al, 2005). Thus, loss of FBW7 function as a result of
gene mutation, epigenetic dysregulation, or posttranslational modification has been found
to cause chromosomal instability and tumorigenesis (Rajagopalan et al, 2004; Loeb et al,
2005), in addition to conferring chemoresistance (Lin et al, 2018). For example,
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dysregulation of myc expression and activity because of loss of function of FBW7 leads to
leukemia in mice (Sharma et al, 2006).
Therefore, FBW7 is primarily considered to be a tumor suppressor, and a single
mutation can have far reaching consequences. FBW7 loss-of-function mutations or
deletions are identified in several cancers. Deletions can be found occasionally in breast,
intestine, and bone cancers (Akhoondi et al, 2007), but are most commonly identified in Tcell lymphoblastic leukemia (Thompson et al, 2007). Deletion of FBW7 has further been
found to cause premature loss of hematopoietic stem cells by promoting cell cycle entry
and apoptosis in a p53-dependent manner. Provided p53 loss also leads to unchecked cell
proliferation, FBW7 and p53 may act together to prevent tumorigenesis (Minella et al,
2007). Most tumorigenic FBW7 point mutations are missense mutations of residues crucial
to the protein-substrate interface which interfere with FBW7 substrate recruitment and
inhibit SCF-dependent turnover of oncogenic substrates (Knuutila et al, 1999). Other
mutations inactivate FBW7 by interfering with its localization, mutating the F-box domain,
or prematurely terminating translation (Sgambato et al, 2007).
Structurally, FBW7 is composed of three basic domains. The first is the dimerization
domain at the N-terminus. Located just before the F-box, this domain facilitates FBW7
dimerization. Though other F-box proteins have also been shown to dimerize, the in vivo
effect of dimerization on substrate selection and ubiquitylation remains unclear. Substratespecific dimerization might reflect degron strength, as dimerization enables recognition of
two degrons in the substrate, allowing FBW7 to target substrates despite weaker degron
interactions (Welcker et al, 2007). The second region is the F-box domain, which binds to
SCF through direct interaction with SKP1 (Hao et al, 2007). The final and largest domain
13

is a stretch of eight WD40 repeats which make multiple contacts with the substrate (Orlicky
et al, 2003). Crystallographic analysis has shown FBW7’s WD40 domain is an 8-bladed
barrel-shaped B-propeller structure with defined phospho-degron binding pockets (Hao et
al, 2007). WD40 repeats 3 and 4 contain three highly conserved arginine residues which
form central contacts with phosphorylated substrates, while additional repeats contribute
to stronger substrate binding.
Many FBXW proteins, including FBW7 and FBXW1A (also known as β-TRCP1), bind
the degron pS/T-P-P-X-pS/T. Located within the substrate, this phospho-degron contains
a priming phosphorylation site (on the right) and a GSK3 target site (on the left) (Punga et
al, 2006). GSK3 kinase stimulates degradation of several, if not all, FBW7 substrates by
phosphorylating the phospho-degron. GSK3 often uses a priming phosphorylation for
binding in order to properly target an acceptor site. The priming-dependent
phosphorylation by GSK3 generates the optimal consensus motif required for FBW7
binding (Welcker et al, 2003). This GSK3 phosphorylation also allows for additional
regulation of substrate ubiquitination through GSK3’s regulation by the PI3K-Akt
pathway. For instance, mitogen signals activate Akt, which in turn inhibits GSK3 and
prevents FBW7 from degrading proteins central to different aspects of mitogenic signaling.
Therefore, when mitogenic signal is low and GSK3 activity is upregulated, FBW7
substrates become fully phosphorylated within their phospho-degrons. This regulation may
allow cells to downregulate cell growth and division rapidly and coordinately in response
to antiproliferative signals (Fresno et al, 2004).

14

H.

Hypothesis and Specific Aims
Despite the identification of USP20 as a positive regulator of ERK3 stability, the E3

ligase responsible for ubiquitinating ERK3 has yet to be identified. As mentioned above,
ERK3 has long been known to be primarily regulated through its stability, undergoing
constitutive degradation by the ubiquitin-proteasome system (Coulombe et al, 2003).
Interestingly, scanning of ERK3 protein sequence identified multiple instances of the
putative phospho-degron sequence pS/T-X-X-X-pS/T located in different regions of
ERK3. We subsequently performed an F-box protein siRNA library screening and found
knockdown of FBW7 resulted in a remarkable increase in ERK3 protein level, suggesting
its potential as a negative regulator of ERK3 (Fig. 5). This led us to hypothesize that FBW7
negatively regulates ERK3 protein stability. In pursuit of the hypothesis, we aim to (1)
determine the role of FBW7 in regulating ERK3 protein stability and (2) study the
interaction by which FBW7 modifies ERK3.
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II.

Materials and Methods

A.

Cell Culture and Reagents:
HEK293T and A549 cells were obtained from American Type Culture Collection
(ATCC). Cells were cultured in Dublecco’s Modified Eagle’s Medium (DMEM) and
Roswell Park Memorial Institute Medium (RPMI), respectively. HCT-116 FBW7 -/cells were a kind gift from Dr. B. Volgestein’s Lab, John’s Hopkins School of
Medicine, and were cultured in McCoy’s 5A (modified) media. All media were
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics penicillinstreptomycin (pen-strep). All media was purchased from ThermoFisher Scientific.

B.

DNA constructs:
All DNA constructs were sourced from pre-existing projects in our lab. The
following constructs used were generated with an N-terminal flag-tag and mammalian
expression: pSG5-Flag-ERK3, pSG5-Flag-ERK3 1-340, pSG5-Flag-ERK3 1-481,
pSG5-Flag-ERK3ΔC34, and pSG5-Flag-ERK3 C34. An additional construct, pSG5Flag-ERK3 341-721, was described previously (Elkhadragy, 2017). Constructs pSG5HA-ERK3, pSG5-HA-ERK3 1-481, and pSG5-HA-ERK3 1-340 were generated with
an N-terminal HA-tag. pcDNA-HA-FBW7 was a gift from Yadi Wu, University of
Kentucky-Lexington. Development of pcDNA-FBW7 was described previously
(Morel et. al, 2020). The F-box was deleted from pcDNA-FBW7 using the primers
FBW7delFbox-R 5'-tcaatcccctcttctttgcacaatgaaatgaagtctcgttg-3' and FBW7ΔFbox-F
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5'-caacgagacttcatttcattgtgcaaagaagaggggattga-3' to create pcDNA-FBW7ΔFbox. pSG5
empty vector, pcDNA empty vector, and pcDNA-HA-GFP were used as control
vectors.
C.

Plasmids and siRNAs transfection:
Cells were transfected with either FuGENEHD (Active motiv, USA) or
Lipofectamine 3000 Reagent (Invitrogen/ThermoFisher Scientific, USA) in
accordance with manufacturer instructions. Unless otherwise noted, cells were
harvested 40 hours after transfection. Silencing experiments utilized Dharma-FECT
Transfection Reagent (Dharmacon, USA) according to manufacturer protocol. Ambion
(USA) supplied both Silencer Select Negative Control and Silencer Select siRNA for
FBXW7. Cells undergoing silencing were harvested 72 hours after transfection.

D.

Western blotting:
Cells were washed briefly with PBS (ThermoFisher Scientific) before lysis with
EBC lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 0.5% NP-40, 1 mM complete
protease inhibitors [Roche Diagnostics] and 1 mM Phosphatase Inhibitor Cocktail III
[Sigma-Aldrich]). 5X SDS sample buffer was added to lysates prior to boiling for 5
minutes at 90°C. Proteins were separated on a 10% gel via SDS-PAGE prior to transfer
onto nitrocellulose membrane by Western blot. Membranes were blocked in 5% nonfat milk in Tris-buffered saline with Tween 20 (TBS-T) for between 30 minutes and 1
hour, after which they were incubated with primary antibody overnight at 4°C while
rocking. Incubation with secondary antibody (HRP-conjugated goat anti-mouse [1706516, Biorad] or anti-rabbit [170-6515, Biorad]) was performed for 1 hour at room
temperature whilst rocking. Blots were visualized via chemiluminescence
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(ThermoFisher). Primary antibodies used were anti-FBW7 (A301-721A, 1:10000,
ThermoFisher), anti-ERK3 (ab53277, 1:1000, Abcam), anti-HA (H3663, 1:10000,
Sigma Aldrich), and anti-Flag (F1804, 1:10000, SigmaAldrich). Loading controls used
were anti-β-actin (A5316, 1:5000, Sigma Aldrich) or anti-GAPDH (Cell Signaling
Technologies, no. 2118).
E.

Immunoprecipitation
Cell transfection and lysis were performed as described above. Prior to lysis, cells
were treated with 10 μM MG-132 for three hours. Protein lysates were pre-cleared
using protein A affinity gel beads (Sigma-Aldrich Cat#P6486) with continuous rotation
at 4°C for 30 minutes. Pre-cleared lysates were incubated with anti-HA affinity agarose
beads (Sigma-Aldrich Cat#E6779) for 3 hours at 4°C while rotating. As a control, preclear lysates were incubated with specific anti-mouse IgG for 1.5 hours. Beads were
washed 3 times using EBC lysis buffer and rotating for 5 minutes at 4°C, followed by
addition of 2X SDS sample buffer. Samples were boiled for 5 minutes at 90°C before
SDS-PAGE and Western blotting as described above.

F.

Cycloheximide Chase Assay
To determine protein stability, cells were treated with protein translation inhibitor
cycloheximide (Kao et al, 2015). Transfection was performed as described above. 40
hours following transfection, cells were treated with 100 ug/mL cycloheximide diluted
in serum-free media (SFM) specific to each cell line (described above). Cells were
lysed using EBC buffer at 30-minute intervals following initial treatment. Protein level
was visualized using Western blotting as described above. Half-life was calculated
using a one-phase decay non-linear regression in GraphPad Prism 9.
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G.

Statistical Analysis
ImageJ was used to quantify relative intensity of Western blot signals. GraphPad
Prism 9 was used for data analysis and graphing. Data is expressed as a mean ± standard
deviation (SD), with a P-value of less than 0.05 being considered significant. Statistical
significance was determined for columnal data using an unpaired two-tailed Student’s
t-test and equal variance was assumed. A one-phase decay non-linear regression
analysis was used to model an approximate decay of each protein. To confirm the effect
of FBW7 was statistically significant, an ANOVA F-test was used to compare decay
models (Mishra et al, 2019).
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III. Results
A.

FBW7 negatively regulates ERK3 protein level.
In order to recruit substrates to their SCF E3 ligase complex, some F-box proteins,
including FBW7, recognize and bind the phospho-degron sequence pS/T-X-X-X-pS/T
located within a substrate protein (Punga et al, 2006). Interestingly, we have found
ERK3 protein contains multiple putative phospho-degron sequences located
throughout its structure (Fig. 4), suggesting ERK3 may be a substrate of SCF E3
ligase(s). As such, we performed a gene knockdown screening using a small siRNA
library against human F-box protein genes to identify which F-box protein may regulate
ERK3 protein level. We found that ERK3 protein level was remarkably altered by the
depletion of each of several F-box proteins, including FBW7 (Fig. 5).

Figure 4. Schematic representation of phospho-degron sequence S/T-X-X-X-pS/T sites
on ERK3
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Figure 5. Western blot of ERK3 protein following siRNA library against human Fbox protein genes. Courtesy of Dr. Marion Morel.
As FBW7 is a well-known tumor suppressor in lung and breast cancers (Wang et
al, 2014), we decided to select FBW7 for further verification. To that end, FBW7 and
ERK3 were co-overexpressed in HEK293T cells. Upon overexpression of FBW7, a
significant decrease was seen in ERK3 protein level (Fig. 6a). We next wanted to
confirm this effect was seen on endogenous ERK3. FBW7 was overexpressed in
HEK293T cells, and overexpression of FBW7 again significantly decreased
endogenous ERK3 protein (Fig. 6b), although the effect was lesser than in the cooverexpression condition.
We next wanted to confirm the result of the initial siRNA screening by silencing
FBW7 in A549 cells and identifying the effect on endogenous ERK3. Consistently,
cells transfected with siFBW7 were correlated with increased ERK3 protein as
compared to those transfected with the siCtrl (Fig. 7). To further confirm the regulation
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of ERK3 by FBW7, we obtained the FBW7 knockout cell line HCT-116 FBW7 -/(Rajagopalan et al, 2004). Consistent with the effect of FBW7 depletion using siRNA,
ERK3 protein level was increased in HCT-116 FBW7 -/- compared to in parental HCT116 cells (Fig. 8). We wanted to confirm whether the increase in ERK3 protein level
is attributed to FBW7 knock out. To examine this, we re-introduced FBW7 by
transiently overexpressing FBW7 in HCT-116 FBW7 -/- cells. Indeed, ERK3 protein
level was decreased upon restoration of FBW7 expression (Fig. 9).
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Figure 6. Transient overexpression of FBW7 decreases ERK3 protein level.
a) Human embryonic kidney 293 cells were transfected with 200 ng pSG5-ERK3HA and 500 ng of either pcDNA empty vector or pcDNA-FBW7. Cells were
harvested 40 hours after transfection and Western blot was probed using antiHA antibody. Graphical representation of composite data from repeat transient
co-overexpression experiments. b) Using HEK293T cells, 500 ng of either
pcDNA empty vector or pcDNA-FBW7 were transiently overexpressed. Cells
were harvested 40 hours after transfection, and Western blot was probed using
anti-ERK3 antibody. Graphical presentation is an aggregate of repeat
experiments. Values represent mean ± S.D. Significant difference is indicated
with asterisks based on the P values obtained in student’s T test
(****0.00001<P<0.0001).
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Figure 7. Silencing FBW7 results in ERK3 protein increase.
Human lung A549 cells were transfected with 30 nm of either siCtrl or siFBW7.
Cells were harvested 72 hours after transfection and Western blot was visualized
using anti-ERK3 antibody. Endogenous FBW7 appears as two bands, the top of
which is reflective of silencing. Representative Western blot courtesy of Dr. Marion
Morel. Schematic representation is cumulative data from experimental repeats.
Values represent mean ± S.D. Significant difference is indicated with asterisks
based on the P values obtained in student’s T test (*0.01<P<0.05).
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Figure 8. ERK3 protein level is increased upon FBW7 knockout in HCT-116
cells.
Human colon cancer HCT-116 parental and FBW7 -/- cells were allowed to grow
for approximately 72 hours before harvest. A Western blot was performed and
signal visualized using an anti-ERK3 antibody. Endogenous FBW7 appears as two
bands, the top of which is reflective of silencing. Representative Western blot
images. Graphical data is a composite of experimental repeats. Values represent
mean ± S.D. Significant difference is indicated with asterisks based on the P values
obtained in student’s T test (**0.001<P<0.01).
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Figure 9. FBW7-induced ERK3 decrease can be rescued in FBW7 knockout
cells.
Human colon cancer HCT-116 FBW7 -/- cells were transfected with 1 μg empty
pcDNA or pcDNA-FBW7. Cells were harvested 48 hours after transfection and
signal was visualized using Western blot with anit-ERK3 antibody. Graphical data
is a composite of experimental repeats. Values represent mean ± S.D. Significant
difference is indicated with asterisks based on the P values obtained in student’s T
test (**0.001<P<0.01).
B.

FBW7 negatively regulates the stability of ERK3 protein.
As mentioned above, ERK3 is known to be regulated through its abundance in cells
(Coulombe et al, 2003). Provided this abundance is regulated through ERK3’s rate of
degradation by the ubiquitin-proteasome pathway (Coulombe et al, 2004), we expected
FBW7 overexpression would result in a decreased stability of ERK3 protein. Thus,
FBW7 and ERK3 were co-overexpressed in HEK293T cells, followed by treatment
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with cycloheximide, an inhibitor of protein translation, and Western blotting analysis
of ERK3 protein turn over with time (Fig. 10a, b). A significant decrease was seen in
the half-life of ERK3 with FBW7 overexpression, which is indicative of reduction in
ERK3 protein stability.
We wanted to confirm this effect on endogenous ERK3 protein. FBW7 was
transiently overexpressed in HEK293T cells and endogenous ERK3 protein level was
analyzed for change upon cycloheximide treatment. Again, we observed a decrease in
ERK3 protein stability upon FBW7 overexpression, though less pronounced than the
effect of FBW7 on transiently overexpressed ERK3 (Fig. 10c, d).
Next, we wanted to test whether ERK3 stability would be increased upon silencing
of FBW7. A cycloheximide chase experiment was performed using A549 cells
transfected with either siCtrl or siFBW7. Endogenous ERK3 was found to have an
increased stability upon FBW7 silencing as compared to the non-targeting control
group (Fig. 11a, b). Taken these results together, we conclude FBW7 negatively
regulates ERK3 protein level and stability.
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Figure 10. Transient overexpression of FBW7 decreases ERK3 protein stability.
a) HEK293T cells were transfected with 200 ng pSG5-ERK3-Flag and 1μg of
either pcDNA-GFP-HA or pcDNA-FBW7-HA. 40 hours after transfection,
cells were treated with the 100 μg/mL of the protease inhibitor cycloheximide
before harvest at indicated intervals. Western blot signals were visualized using
an anti-Flag antibody. To quantify the relative band intensity from the Western
blots, ImageJ was used. b) Graphical representation of aggregate data from cooverexpression cycloheximide chase experiments. Half Life: Ctrl t1/2= 1.381
hours, FBW7 t1/2= 0.7004 hours, F-test: P<0.0001. c) HEK293T cells were
transfected with 400 ng pcDNA empty vector or pcDNA-FBW7. Aliquots were
treated with 100 μg/mL cycloheximide and harvested at the indicated intervals,
followed by Western blot probed with anti-ERK3 antibody. Western blot
signals were quantified using ImageJ. d) Graphical representation of quantified
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data from FBW7 overexpression cycloheximide chase experiments. Half-life:
Ctrl1/2=1.950 hours, FBW71/2= 0.8842 hours, F-test: P<0.0001. Non-linear
regression was used to calculate half-life, ANOVA F-test used to determine
significance. P<0.05 was considered statistically significant.
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Figure 11. FBW7 silencing increases ERK3 protein stability.
a) A549 cells were transfected with 30 nm non-targeting siRNA (siCtrl) or siRNA
targeted to FBW7 (siFBW7). 72 hours after transfection, cells were treated with
100 μg/mL cycloheximide and harvested at indicated half-hour intervals. Lysed
cells were Western blotted using an anti-ERK3 antibody. Western blot bands were
quantified using ImageJ b) Decay model of aggregate data from repeat
experiments. The difference between the non-targeting siRNA and FBW7-targeted
FBW7 groups was identified as statistically significant using an F-test. Half-life:
siCtrl t1/2= 0.6267 hours, siFBW7 t1/2= 1.847 hours, F-test: P<0.0001. Non-linear
regression was used to calculate half-life, ANOVA F-test used to determine
significance. P<0.05 was considered statistically significant.

C.

The F-box domain of FBW7 is required for FBW7’s regulation of ERK3.
The F-box domain of FBW7 is essential for FBW7 interaction with SKP1 and
subsequent formation of a functional SCF-E3 ligase complex capable of ubiquitinating
substrates (Zhou et al, 2013; Hao et al, 2007). Thus, we reasoned that the F-box domain
is required for FBW7 regulation of ERK3. To investigate the importance of the F-box
domain, we generated a construct expressing FBW7 with the deletion of the F-box
domain (FBW7ΔFbox) (Fig. 12). Using this mutant, we first tested whether the effect
of transiently overexpressed FBW7 on overexpressed ERK3 was lost upon deletion of
the F-box. Overexpression of FBW7 led to a significant decrease in ERK3 protein level
as expected. However, overexpression of FBW7ΔFbox shows a non-significant effect
on ERK3 protein level (Fig. 13a). To confirm this effect on endogenous ERK3, FBW7
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or FBW7ΔFbox were overexpressed in HEK293T cells. Again, we observed a
significant effect of FBW7 on endogenous ERK3 expression, and a non-significant
effect on ERK3 upon FBW7ΔFbox overexpression (Fig. 13b).

Figure 12. Schematic representation of wild type FBW7 and the FBW7ΔFbox
mutant.
We then investigated the importance of the F-box domain in FBW7’s regulation of
ERK3 stability by performing cycloheximide chase experiment in HEK293T cells. We
transiently overexpressed ERK3-HA and either FBW7 or FBW7ΔFbox, followed by
cycloheximide treatment and Western blotting analysis. Consistent with the effect on
ERK3 protein level, the deletion of F-box domain abolished the effect of FBW7 on
decreasing the stability of either exogenously expressed ERK3 (Figure 14a,b) or
endogenous ERK3 protein (Figure 14c,d). Taken together, we propose the F-box
domain is required for FBW7 to negatively regulate ERK3 protein stability.
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Figure 13. Negative regulation of ERK3 by FBW7 requires the F-box domain.
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a) HEK293T cells were transfected with 200 ng pSG5-ERK3-HA and either 1 μg
pcDNA empty vector, 1 μg pcDNA-FBW7, or 500 ng pcDNA-FBW7ΔFbox
supplemented with 500 ng pcDNA empty vector. 40 hours after transfection, cells
were lysed, and Western blots were probed using an anti-HA antibody.
Quantification of aggregate data showing ERK3 and FBW7/FBW7ΔFbox cooverexpression. Ctrl vs. FBW7: 0.00001<P<0.0001. b) HEK293T cells were
transfected with 1 μg pcDNA empty vector, 1 μg pcDNA-FBW7, or 500 ng
pcDNA-FBW7ΔFbox supplemented with 500 ng pcDNA empty vector. After 40
hours, cells were harvested, and Western blots were probed using anti-ERK3
antibody. Different amounts FBW7 construct DNA were used to account for
differences in stability. Ctrl vs. FBW7: 0.001<P<0.01. Values represent mean ±
S.D. Significant difference is indicated with asterisks based on the P values
obtained in student’s T test.
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Figure 14. The F-box domain is required for negative regulation of ERK3 stability
by FBW7.
a) HEK293T cells were transfected with 200 ng ERK3-HA and 1 μg pcDNA empty
vector, 1 μg pcDNA-FBW7, or 750 ng pcDNA-FBW7ΔFbox supplemented with
250 ng pcDNA empty vector. 40 hours after transfection, cells were treated with
100 μg/mL cycloheximide and harvested at half-hour intervals as indicated.
Westetrn blots were probed with an anti-Flag antibody. b) Graphical model of
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FBW7’s effect on ERK3-Flag decay. Half-Life: Ctrl t1/2= 1.381, FBW7 t1/2=
0.7004, FBW7ΔFbox t1/2= 1.511. F-test (Ctrl v. FBW7ΔFbox): P= 0.5959. c)
HEK293T cells were transfected with either 1 μg pcDNA empty vector, 1 μg
pcDNA-FBW7, or 750 ng pcDNA-FBW7ΔFbox supplemented with 250 ng
pcDNA empty vector. Cells were treated with 100 μg/mL cycloheximide, Western
blots probed with anti-ERK3 antibody. d) Graphical model of FBW7’s effect on
endogenous ERK3 decay. Half-Life: Ctrl t1/2= 1.950, FBW7 t1/2= 0.8842,
FBW7ΔFbox t1/2= 1.977. F-test (Ctrl v. FBW7ΔFbox): P= 0.9369. P<0.05 was
considered statistically significant. Different amounts FBW7 construct DNA were
used to account for differences in stability.
D.

ERK3 interacts with FBW7 via C34 domain.
With this evidence of FBW7 regulation of ERK3, we wanted to investigate
the interaction between ERK3 and FBW7. HEK293T cells were transfected with
ERK3-Flag and FBW7-HA. A co-immunoprecipitation was then performed in
which FBW7 was isolated using HA-conjugated beads. Using Western blotting
analysis, it was found ERK3-Flag complexes with FBW7-HA (Fig. 16a).
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We next wanted to identify which domain of ERK3 is required for its
interaction with FBW7. As described above, ERK3 primarily consists of three
domains: the N-terminal kinase domain, C34, and the C-terminus (Fig. 15). We
created multiple flag-tagged ERK3 deletion mutants: ERK3 kinase domain and C34
domains (1-481), ERK3 kinase domain alone (1-340), ERK3 kinase and C-terminal
domains (ΔC34), and the ERK3 C34 domain alone (C34) (Fig. 15). HEK293T cells
were co-transfected with each of various ERK3 constructs and FBW7-HA,
followed by FBW7 immunoprecipitation and Western blotting. FBW7’s interaction
was identified with full length ERK3 and ERK3 1-481, while no interaction was
seen with either ERK3 1-340 or ERK3 ΔC34, suggesting the interaction required
the presence of the C34 domain (Fig. 16a).

Figure 15. Schematic representation of ERK3 mutant constructs.
To confirm the importance of the C34 domain for ERK3 interaction with
FBW7 and to identify whether the ERK3 C34 domain alone is sufficient for
interaction with FBW7, an immunoprecipitation and Western blotting analysis
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were performed with HEK293T cells co-transfected with FBW7-HA and C34-Flag
(Fig. 16b). An interaction was clearly seen between FBW7 and C34 of ERK3. Thus,
we conclude that the ERK3 C34 domain is both necessary and sufficient for
interaction with FBW7.

Figure 16. FBW7 interacts with ERK3 at the C34 domain.
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a) HEK293T cells were transfected with 4 μg pcDNA-FBW7-HA and either 4 μg
pSG5-Flag-ERK3, 1 μg pSG5-Flag-ERK3 1-481, 750 ng pSG5-Flag-ERK3 1-340,
or 750 ng pSG5-Flag-ERK3ΔC34. 40 hours following transfection, cells were lysed
and FBW7 was immunoprecipitated using HA-conjugated beads or a mouse IgG
control. Lysates were separated and visualized via Western blot using an anti-Flag
antibody. b) HEK293T cells were transfected with 4 μg pcDNA-FBW7-HA and 4
μg pSG5-Flag-ERK3 C34. Cells were lysed and FBW7 was immunoprecipitated
using HA beads or mouse IgG control. Western blotting was used to identify
complex of Flag-tagged proteins with FBW7. Different amounts ERK3 construct
DNA were used to account for differences in stability, and pcDNA empty vector
was used to supplement.

E.

Regulation of ERK3 by FBW7 requires the ERK3 C34 domain.
After identifying the requirement of ERK3 C34 for interaction between
ERK3 and FBW7, we wanted to determine whether this domain was required for
FBW7 regulation of ERK3. To determine the effect of FBW7 on the protein levels
of various ERK3 deletion mutants, HEK293T cells were transfected with pcDNAFBW7 and each of the following tagged ERK3 constructs: ERK3, ERK3 1-481,
ERK3 1-340, ERK3 341-721, and ERK3ΔC34 (Fig. 16). FBW7 overexpression led
to a significant decrease in ERK3 1-481 protein level but had no significant effect
on ERK3 1-340 or ERK3 341-721 (Fig. 17a, b). Interestingly, overexpression of
FBW7 significantly increased ERK3ΔC34 protein level (Fig. 17a, b).
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Next, the importance of ERK3 C34 domain in the regulation of ERK3
protein stability by FBW7 was investigated. HEK293T cells were transfected with
FBW7 and one of the following ERK3 constructs: ERK3 1-481, ERK3 1-340,
ERK3 341-721, or ERK3ΔC34, and cycloheximide chase experiments were
performed to compare rates of protein degradation. The effects of FBW7 on ERK3
stability were generally reflective of the effects on the total protein level of each
ERK3 mutant. FBW7 overexpression led to a significance decrease in ERK3 1-481
protein stability (Fig. 18a, b), but had little effect on ERK3 1-340 (Fig. 18c, d),
ERK3 341-721 (Fig. 18e, f), or ERK3ΔC34 (Fig. 18g, h).
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Figure 17. The C34 domain is required for FBW7-mediated decrease of ERK3
protein.
a) HEK293T cells were transfected with 1 μg pcDNA-FBW7 and 200 ng of one
of the following constructs: pSG5-Flag-ERK3, pSG5-Flag-ERK3 1-481, pSG5Flag-ERK3 1-340, pSG5-Flag-ERK3 341-721, or pSG5-Flag-ERK3ΔC34.
After 40 hours, cells were harvested, and Western blots were probed using antiHA or anti-Flag antibody. Representative Western blots. b) Graphical
representation of effect of FBW7 on various ERK3 constructs. Values represent
mean ± S.D. Significant difference is indicated with asterisks based on the P
values obtained in student’s T test (**0.001<P<0.01, ***0.0001<P<0.001,
****0.00001<P<0.0001).
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Figure 18. The C34 domain is required for FBW7-induced ERK3 instability.
Western blot and graphical models of FBW7’s effect on the decay of various
ERK3-Flag constructs. HEK293T cells were transfected with 1 μg FBW7 and 200
ng of one of the following ERK3 constructs: pSG5-Flag-ERK3 1-481, pSG5-FlagERK3 1-340, pSG5-Flag-ERK3 341-721, or pSG5-Flag-ERK3ΔC34. 40 hours
after transfection, cells were treated with 100 μg/mL cycloheximide and harvested
at half-hour intervals as indicated. a, b) Western blot and graphical model of ERK3
1-481 decay. Half-life: Ctrl t1/2= 1.836 hrs., FBW7 t1/2= 0.8994 hrs. F-test:
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P<0.0001. c, d) Western blot and graphical model of ERK3 1-340 decay. Half-life:
Ctrl t1/2= 3.562 hrs., FBW7 t1/2= 3.838 hrs. F-test: P= 0.7228. e, f) Western blot and
graphical model of ERK3 341-721 decay. Half-life: Ctrl t1/2= 0.9217 hrs., FBW7
t1/2= 0.8348 hrs. F-test: P= 0.4382. g, h) Western blot and graphical model of
ERK3ΔC34 decay. Half-life: Ctrl t1/2= 1.414 hrs., FBW7 t1/2= 1.288 hrs. F-test: P=
0.5768. P<0.05 was considered significant.
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IV. Discussion
While conventional MAPKs are typically regulated through phosphorylation of their
activation loop by MEKs (e.g. MEK1/2), ERK3 is regulated primarily through its continual
degradation via the ubiquitin-proteasome pathway (Coulombe et al, 2003). This
degradation is regulated, in part, through the deubiquitinating enzyme USP20 (Mathien et
al, 2017). The E3 ligase that induces ERK3 protein ubiquitination and proteasomal
degradation has yet to be identified. In the current study, we have identified FBW7 alters
ERK3 by destabilizing the protein and decreasing its protein level in cells. Additionally,
we have identified the negative regulation of ERK3 by FBW7 requires the F-box domain
of FBW7 and the C34 domain of ERK3, with the latter being sufficient to direct ERK3 and
FBW7 interaction.
FBW7 has been identified as a tumor suppressor for its role in promoting
degradation of a number of oncoproteins (e.g. myc) (Welcker et al, 2004; Strohmaier et al,
2001; Klinakis et al, 2006; Wei et al, 2005; Sharma et al, 2006), and loss-of-function
mutations which disrupt FBW7’s activity have been implicated in various cancers (Wang
et al, 2014; Cheng and Li, 2012). FBW7 inhibits cell cycle progression and proliferation
while promoting apoptosis (Yeh et al, 2018). Conversely, ERK3 has been found to be
upregulated in several cancers including cancers of the lung and breast (Lei et al, 2014),
having been shown to promote cell growth (Wang et al, 2014) and differentiation
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(Klinger et al, 2009). Both inhibition of FBW7 and upregulation of ERK3 have been found
to promote cell migration and invasion (Jin et al, 2017; Alsaran et al, 2017). In particular,
colorectal cancer and non-small cell lung cancer are both linked with FBW7 inhibition and
ERK3 upregulation (Li et al, 2018; Zhang et al, 2018; Long et al, 2012; Wang et al, 2000).
Therefore, though we have not investigated the role of FBW7-ERK3 on tumor metastasis,
this study suggests that the disruption of the FBW7-ERK3 axis may impact cancer cell
migration and invasion via ERK3 upregulation. Our study provides insight into a
previously unidentified negative regulator of ERK3 and this association should be further
explored through investigation of negative correlation between ERK3 and FBW7
expression levels in a clinical setting in addition to identifying the role of FBW7 loss-offunction mutations in aberrant ERK3 signaling.
ERK3 itself has previously been recommended as a potential therapeutic target due
to its upregulation in certain forms of treatment-resistant lung cancers (Long et al, 2012)
and critical role in mediating breast cancer cell seeding and lung metastasis (Bogucka et
al, 2020). Loss of ERK3 was also shown to prevent KRAS-driven oncogenesis in NSCLC
tumors (Bogucka et al, 2021). However, while kinase inhibitors have proved powerful in
anti-cancer treatment, they nevertheless produce off-target effects which may result in
activation of linked pathways (Wynn et al, 2011). Provided the implication of FBW7
dysfunction in a number of cancers, research into FBW7 as a potential therapeutic target is
ongoing (Liu et al, 2020). Kim et al (2021) showed increased FBW7 expression as a result
of decitabine treatment suppressed lung cancer cell growth. Similarly, a subgroup of nonsmall cell lung cancer patients was found to have developed therapy resistance upon loss
of FBW7, with patients becoming therapy responsive upon FBW7 reactivation (Ye et al,
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2017). Thus, identification of ERK3 as a substrate of FBW7 may provide an avenue for
further investigation during the development of these targeted therapeutics, in addition to
providing a possible mechanism by which to target aberrant ERK3 expression.
We found the effect of FBW7 was lost on an ERK3 mutant lacking the N-terminal
kinase domain (ERK3 341-721) (Fig. 17, 18e, f). This corroborates the findings of
Coulombe et al (2003), which identified destabilization signals located within the Nterminus. Furthermore, the importance of the N-terminal kinase domain for FBW7's effect
on ERK3 may provide indication of SCFFBW7 ubiquitination site(s) in the N-terminus.
In the case of ERK3 1-340, we saw neither protein stability nor total protein level
were affected by FBW7 overexpression (Fig. 17, 18c, d). Though there was no change
upon FBW7 overexpression, there was a significant increase in stability of ERK3 1-340 as
compared to full length ERK3 (Fig. 18d Ctrl t1/2= 3.562 hrs., 10b Ctrl t1/2= 1.381 hrs.; Ftest: P<0.0001). The loss of the C-terminus of the ERK3 1-340 mutant as compared to full
length ERK3 might contribute to the overall increase in half-life regardless of FBW7
overexpression. The C-terminal extension contains a number of lysine residues which may
serve as potential ubiquitination sites. It is worth noting the landmark study on ERK3
ubiquitination sites did not investigate the C-terminal extension upon mapping (Coulombe
et al, 2004), citing ubiquitination as confined to the first 365 amino acids of ERK3
according to their previous work (Coulombe et al, 2003). However, the Coulombe et al
(2003) study does not exclude the possibility of additional ubiquitination of the C-terminal
region. Though it identifies the deletion of the C-terminal (defined in the study as amino
acids 365-721) does not prevent ERK3 degradation, no investigation was done on potential
additional, non-mandatory ubiquitination sites. Additional ubiquitination chains have been
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shown to modulate rate of degradation (Bard et al, 2018), conferring additional affinity for
the proteasome whilst not being required for degradation (Lu et al, 2015; Shabek et al,
2012). Though the study did show a C-terminal mutant as having increased stability
compared to the wild type, the ERK3 segment used includes amino acids 199-721
(Coulombe et al, 2003). As this mutant contains both the C-terminal, C34 domain, and a
portion of the kinase domain, it may undergo additional stabilizing regulation incapable of
being exacted on the canonical truncated C-terminus (481-721) (Fig. 16). As such, it is
possible the C-terminal region contains additional ubiquitination sites which, though not
required for ERK3 degradation by the proteasome, aid in targeting ERK3 for destruction.
Therefore, the loss of this C-terminal region could result in diminished interaction between
ERK3 1-340 and the 26S proteasome, thereby stabilizing ERK3 1-340 irrespective of
FBW7 overexpression.
Though theoretical, the presence of additional ubiquitin sites on the C-terminal
domain does provide explanation for stability differences among various ERK3 mutants
used. Despite being unaffected by FBW7 overexpression, ERK3 341-721 has a
significantly shorter half-life than full length ERK3 (Fig. 18f Ctrl t1/2= 0.9217 hrs., 10b
Ctrl t1/2= 1.381 hrs.; F-test: P< 0.01) and ERK3 1-481 is more stable than full length ERK3
(Fig. 18b Ctrl t1/2= 1.836 hrs., 10b Ctrl t1/2= 1.381 hrs.; F-test: P<0.05) regardless of its
alteration by FBW7. It may be of interest in future studies to identify whether the Cterminus contains ubiquitination sites and the different E3 ligase responsible for their
ubiquitination.
In considering potential pitfalls of the study, our results could be corroborated by
using additional proteasome inhibitors as MG-132 has been shown to have off-target
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effects (Mitchell and Samulski, 2013). Provided our use of a number of truncated ERK3
mutants, it also would be beneficial to identify a potential effect of ERK3 localization on
its regulation by FBW7. Bind et al (2004) showed ERK3 to be both nuclear and
cytoplasmic with localization controlled by cleavage. Upon cleavage of the carboxy
terminus, a truncated ERK, consisting of amino acids 1-376 and as many as 224 additional
residues of the carboxy terminal, travels to the nucleus (Bind et al, 2004). Our study does
provide evidence of interaction between FBW7 and truncated ERK3 mutants, but future
investigation should utilize fluorescent microscopy to identify co-localization of FBW7
and ERK3, and whether a specific domain of ERK3 is required for this co-localization.
Additionally, cell fractionation may be used to identify whether FBW7-ERK3 interaction
or ERK3 ubiquitination is limited to a specific organelle(s), and if this is changed upon
ERK3 mutation. Additionally, provided the apparent role of ERK3 accumulation in cell
cycle regulation (Coulombe et al, 2003; Tanguay et al, 2010), it may be of interest for
future experiments to utilize cell synchronization to investigate potential positive
correlation between the regulation of ERK3 by FBW7 and dephosphorylation of ERK3 by
Cdc14A and Cdc14B (Kostenko et al, 2011).
Much remains to be identified in future research regarding ERK3’s regulation by
FBW7. Though initial data shows FBW7 increases ubiquitination of ERK3 (unpublished
data from our lab), the detailed mechanisms by which FBW7 regulates ERK3
ubiquitination (e.g. SCFFBW7) remain to be identified. Likewise, while we speculate as to
the ubiquitination sites of ERK3 targeted by FBW7, evidence is still needed to confirm
these site-specific modifications. Ubiquitination sites may be investigated through
mutation of potential lysine residues as described by Coulombe et al (2004). Provided its
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frequent cooperation with FBW7 in targeting substrates for ubiquitination and degradation,
the role of GSK3 on FBW7-mediated ERK3 regulation should be investigated in future
work. Returning to our initial identification of GSK3 target sites, ERK3 contains a single
phospho-degron within the C34 domain, which is T417NYST. Here, GSK3 can theoretically
utilize a previously phosphorylated T421 to target and phosphorylate the critical threonine
T417 to create the optimal consensus motif of two phosphorylation sites spaced three
residues apart required for FBW7 binding. Initial confirmation of GSK3 involvement can
be accomplished through use of any number of commercially available specific inhibitors
to constrain GSK3 and subsequently identify the effect on ERK3 protein level and stability
in the presence of FBW7. Confirmation of this site as a phospho-degron can be
accomplished through mutation of the ERK3 T417 and/or T421 into an alanine residue.
Additionally, a co-immunoprecipitation of ERK3 and GSK3 can help identify ERK3 as a
substrate for the latter.
In summary, we initially identified FBW7 as capable of regulating ERK3 protein
level. Subsequently, we established this regulation occurs through FBW7’s destabilization
of ERK3 protein. We identified the FBW7 F-box domain is required for FBW7 regulation
of ERK3, a potential indication SCF plays a role in ERK3 degradation, though more
research is required. Finally, we identified the ERK3 C34 domain is necessary for FBW7
regulation of ERK3 and is itself sufficient for FBW7-ERK3 interaction. Thus, we propose
FBW7 negatively regulates ERK3 protein stability in a manner dependent on the FBW7 Fbox and ERK3 C34 domains.
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